Matthijs Versteegh
Overview
Explore the profile of Matthijs Versteegh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsuan Chen Y, Kroesen M, Hoogeman M, Versteegh M, Uyl-de Groot C, Blommestein H
Clin Transl Radiat Oncol
. 2025 Feb;
51:100913.
PMID: 39898329
Objective: In comparison to current standard photon irradiation, proton therapy (PT) significantly reduces dose to the surrounding normal tissue and therefore is expected to reduce toxicity and improve health related...
2.
van Hezik-Wester V, de Groot S, Kanters T, Wagner L, Ardesch J, Brouwer W, et al.
Value Health
. 2024 Aug;
27(12):1679-1688.
PMID: 39127247
Objectives: The Epilepsy Support Dog Evaluation study was commissioned by the Dutch Ministry of Health, Welfare and Sports to inform a reimbursement decision on seizure dogs. The randomized trial found...
3.
Smets I, Versteegh M, Huygens S, Wokke B, Smolders J
Mult Scler
. 2024 Jun;
30(8):1016-1025.
PMID: 38859625
Background: Uncertainty about disproportionate impact on health care budgets limits implementation of early highly effective treatment (EHT) in multiple sclerosis (MS). Objective: To estimate cost-effectiveness of escalation versus EHT disease-modifying...
4.
van Hezik-Wester V, de Groot S, Kanters T, Wagner L, Ardesch J, Brouwer W, et al.
Neurology
. 2024 Feb;
102(6):e209178.
PMID: 38417090
Background And Objectives: The aim of this study was to evaluate whether people living with severe medically refractory epilepsy (PSRE) benefit from a seizure dog. Methods: An individual-level stepped-wedge randomized...
5.
Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al.
Per Med
. 2023 Sep;
20(4):321-338.
PMID: 37746727
To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. Four testing strategies where adult cancer patients received entrectinib if they tested positive for gene fusions ...
6.
Rutten-van Molken M, Versteegh M, Nagy B, Wordsworth S
Per Med
. 2023 Sep;
20(4):299-303.
PMID: 37736874
No abstract available.
7.
Nagy B, Zelei T, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, et al.
Per Med
. 2023 Sep;
20(4):401-411.
PMID: 37694556
The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. In three therapeutic areas, health economic models were developed to scrutinize the...
8.
Kovacs G, Nagy D, Szilberhorn L, Zelei T, Gaal Z, Vellekoop H, et al.
Per Med
. 2023 Sep;
20(4):375-385.
PMID: 37694384
Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which...
9.
Szilberhorn L, Zelei T, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, et al.
Per Med
. 2023 Sep;
20(4):387-399.
PMID: 37665262
Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. A diabetes model was adapted...
10.
Koleva-Kolarova R, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, Szilberhorn L, et al.
Per Med
. 2023 Sep;
20(4):339-355.
PMID: 37665240
The aim of this study was to evaluate the cost-effectiveness of ToxNav, a multivariant genetic test, to screen for followed by personalized chemotherapy dosing for metastatic breast cancer in the...